Prevention of sickness absence through early identification and rehabilitation of at-risk patients with musculoskeletal
- PDF / 994,879 Bytes
- 13 Pages / 595.276 x 790.866 pts Page_size
- 89 Downloads / 190 Views
(2020) 21:790
STUDY PROTOCOL
Open Access
Prevention of sickness absence through early identification and rehabilitation of atrisk patients with musculoskeletal pain (PREVSAM): a randomised controlled trial protocol MEH Larsson1,2* , L. Nordeman2,3, K. Holmgren4, A. Grimby-Ekman5, G. Hensing5, C. Björkelund6, S. Bergman6, A. Ekhammar1,2, M. Dottori1 and S. Bernhardsson1,2
Abstract Background: Musculoskeletal pain is globally a leading cause of physical disability. Many musculoskeletal-related pain conditions, such as low back pain, often resolve spontaneously. In some individuals, pain may recur or persist, leading to ong-term physical disability, reduced work capacity, and sickness absence. Early identification of individuals in which this may occur, is essential for preventing or reducing the risk of developing persistent musculoskeletal pain and long-term sickness absence. The aim of the trial described in this protocol is to evaluate effects of an early intervention, the PREVSAM model, on the prevention of sickness absence and development of persistent pain in at-risk patients with musculoskeletal pain. Methods: Eligible participants are adults who seek health care for musculoskeletal pain and who are at risk of developing persistent pain, physical disability, and sickness absence. Participants may be recruited from primary care rehabilitation centres or primary care healthcare centres in Region Västra Götaland. Participants will be randomised to treatment according to the PREVSAM model (intervention group) or treatment as usual (control group). The PREVSAM model comprises an interdisciplinary, person-centred rehabilitation programme, including coordinated measures within primary health care, and may include collaboration with participants’ employers. The primary outcome sickness absence is operationalised as the number and proportion of individuals who remain in full- or part-time work, the number of gross and net days of sickness absence during the intervention and follow-up period, and time to first sickness absence spell. Secondary outcomes are patient-reported short-term sickness absence, work ability, pain, self-efficacy, health-related quality of life, risk for sickness absence, anxiety and depression symptoms and physical disability at 1 and 3 months after inclusion (short-term follow-up), and at 6 and 12 months (long-term follow-up). A cost-effectiveness analysis is planned and drug consumption will be investigated. (Continued on next page)
* Correspondence: [email protected] 1 Department of Education, Research and Development Primary Health Care, Region Västra Götaland, Gothenburg, Sweden 2 Unit of Physiotherapy, Department of Health and Rehabilitation, Institute of Neuroscience and Physiology, The Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden Full list of author information is available at the end of the article © The Author(s). 2020 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, ada
Data Loading...
